Ontario is the eighth Canadian jurisdiction to switch patients with Crohn's disease and other conditions from life-changing biologic drugs to more cost-effective 'biosimilars.' Both options are considered effective, and the swap saves millions. But should patients be forced to make the change?
Post a Comment